Overweight and obesity predict better overall survival rates in cancer patients with distant metastases

Cancer Medicine

Volumn 5, Issue 4, 2016, Pages 665-675

  Tsang, Ngan Ming ^a,b   Pai, Ping Ching ^a   Chuang, Chi Cheng ^a   Chuang, Wen Ching ^c   Tseng, Chen Kan ^a   Chang, Kai Ping ^a   Yen, Tzu Chen ^a   Lin, Jen Der ^a   Chang, Joseph Tung Chieh ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

BMI; Body mass index; Metastatic cancer; Obesity; Overall survival

Indexed keywords

ADULT; AGED; ARTICLE; BODY MASS; CANCER RADIOTHERAPY; DISTANT METASTASIS; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; UNDERWEIGHT; VERY ELDERLY; COMPLICATION; HEALTH SURVEY; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; NEOPLASMS; PATHOLOGY; PROGNOSIS; TAIWAN; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; OBESITY; OVERWEIGHT; POPULATION SURVEILLANCE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN; YOUNG ADULT;

EID: 85006223080     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.634     Document Type: Article

References (44)

1. Sporn, M. B. 1996. The war on cancer. Lancet 347:1377-1381.
2. Goldberg, R. M. 2006. Therapy for metastatic colorectal cancer. Oncologist 11:981-987.
3. Roche, H., and L. T. Vahdat . 2011. Treatment of metastatic breast cancer: second line and beyond. Ann. Oncol. 22:1000-1010.
4. Scagliotti, G. V., P. Parikh, J. von Pawel, B. Biesma, J. Vansteenkiste, C. Manegold, et al. 2008. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 26:3543-3551.
5. Fong, Y., J. Fortner, R. L. Sun, M. F. Brennan, and L. H. Blumgart . 1999. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann. Surg. 230:309-318.
6. Mutsaerts, E. L., F. A. Zoetmulder, S. Meijer, P. Baas, and A. A. Hart . 2001. Outcome of thoracoscopic pulmonary metastasectomy evaluated by confirmatory thoracotomy. Ann. Thorac. Surg. 72:230-233.
7. Tendulkar, R. D., S. W. Liu, G. H. Barnett, M. A. Vogelbaum, S. A. Toms, T. Jin, et al. 2006. RPA classification has prognostic significance for surgically resected single brain metastasis. Int. J. Radiat. Oncol. Biol. Phys. 66:810-817.
8. Gaspar, L., C. Scott, M. Rotman, S. Asbell, T. Phillips, T. Wasserman, et al. 1997. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int. J. Radiat. Oncol. Biol. Phys. 37:745-751.
9. Romero-Corral, A., V. M. Montori, V. K. Somers, J. Korinek, R. J. Thomas, T. G. Allison, et al. 2006. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 368:666-678.
10. Voulgari, C., N. Tentolouris, P. Dilaveris, D. Tousoulis, and N. Katsilambros . 2011. Increased heart failure risk in normal-weight people with metabolic syndrome compared with metabolically healthy obese individuals. J. Am. Coll. Cardiol. 58:1343-1350.
11. Kalantar-Zadeh, K., E. Streja, M. Z. Molnar, L. R. Lukowsky, M. Krishnan, C. P. Kovesdy, et al. 2012. Mortality prediction by surrogates of body composition: an examination of the obesity paradox in hemodialysis patients using composite rankingscore analysis. Am. J. Epidemiol. 175:793-803.
12. Schmidt, D. S., and A. K. Salahudeen . 2007. Obesity-survival paradox-still a controversy? Semin. Dial. 20:486-492.
13. Flegal, K. M., B. K. Kit, H. Orpana, and B. I. Graubard . 2013. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 309:71-82.
14. Renehan, A. G., M. Tyson, M. Egger, R. F. Heller, and M. Zwahlen . 2008. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569-578.
15. Peto, J. 2001. Cancer epidemiology in the last century and the next decade. Nature 411:390-395.
16. Calle, E. E., C. Rodriguez, K. Walker-Thurmond, and M. J. Thun . 2003. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 348:1625-1638.
17. Sparano, J. A., M. Wang, F. Zhao, V. Stearns, S. Martino, J. A. Liqibel, et al. 2012. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer 118:5937-5946.
18. Zhang, S. S., H. Yang, K. J. Luo, Q. Y. Huang, J. Y. Chen, F. Yang, et al. 2013. The impact of body mass index on complication and survival in resected oesophageal cancer: a clinical-based cohort and meta-analysis. Br. J. Cancer 109:2894-2903.
19. Choi, Y., B. Park, B. C. Jeong, S. I. Seo, S. S. Jeon, H. Y. Choi, et al. 2013. Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis. Int. J. Cancer 132:625-634.
20. Dahlberg, S. E., J. H. Schiller, P. B. Bonomi, A. B. Sandler, J. R. Brahmer, S. S. Ramalingam, et al. 2013. Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trial. J. Thorac. Oncol. 8:1211-1217.
21. Eroglu, C., O. Orhan, H. Karaca, D. Unal, M. Dikilitas, M. Ozkan, et al. 2013. The effect of being overweight on survival in patients with gastric cancer undergoing adjuvant chemoradiotherapy. Eur. J. Cancer Care (Engl) 22:133-140.
22. Pai, P. C., C. C. Chuang, C. K. Tseng, N. M. Tsang, K. P. Chang, T. C. Yen, et al. 2012. Impact of pretreatment body mass index on patients with head-and-neck cancer treated with radiation. Int. J. Radiat. Oncol. Biol. Phys. doi:10.1016/j.ijrobp.2011.11.071.
23. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. 2005. Management of hepatocellular carcinoma. Hepatology 42:1208-1236.
24. Agaku, I. T., B. A. King, S. R. Dube, and Centers for Disease Control and Prevention (CDC). 2014. Current cigarette smoking among adults - United States, 2005-2012. MMWR Morb. Mortal. Wkly Rep. 63:29-34.
25. Charlson, M. E., P. Pompei, K. L. Ales, and C. R. MacKenzie . 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic. Dis. 40:373-383.
26. Leete, R., and J. Fox . 1977. Registrar General's social classes: origins and uses. Popul. Trends 8:1-7.
27. Lainsack, M., S. von Haehling, W. Doehner, and S. D. Anker . 2012. The obesity paradox in chronic disease: facts and numbers. J. Cachexia Sarcopenia Muscle 3:1-4.
28. Casas-Vara, A., F. Santolaria, A. Fernández-Bereciartúa, E. González-Reimers, A. García-Ochoa, and A. Martínez-Riera . 2012. The obesity paradox in elderly patients with heart failure: analysis of nutrition status. Nutrition 28:616-622.
29. Collins, J., S. Noble, J. Chester, B. Coles, and A. Byrne . 2014. The assessment and impact of sarcopenia in lung cancer: a systemic literature review. BMJ Open. doi:10.1136/bmjopen.2013.003697.
30. Prado, C. M., V. E. Baracos, L. J. McCargar, T. Reiman, M. Mourtzakis, K. Tonkin, et al. 2009. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin. Cancer Res. 15:2920-2926.
31. Gonzalez, M. C., C. A. Pastore, S. P. Orlanddi, and S. B. Heymsfield . 2014. Obesity paradox in cancer: new insights provided by body composition. Am. J. Clin. Nutr. 99:999-1005.
32. Harimoto, N., K. Shirabe, T. Yamashita, T. Ikegami, T. Yoshizumi, Y. Soejima, et al. 2013. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br. J. Surg. 100:1523-1530.
33. Schaap, L. A., S. M. Pluijm, D. J. Deeg, and M. Visser . 2006. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am. J. Med. doi:10.1016/j.amjmed.2005.10.049.
34. Kuroda, K., J. Nakashima, K. Kanao, E. Kikuchi, A. Miyajima, Y. Horiquchi, et al. 2007. Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology 69:113-117.
35. Lederle, W., S. Depner, S. Schnur, E. Obermuller, N. Catone, A. Just, et al. 2011. IL-6 promotes malignant growth of skin SCCs by regulating a network of autocrine and paracrine cytokines. Int. J. Cancer 128:2803-2814.
36. Sullivan, N. J., A. K. Sasser, A. E. Axel, F. Vesuna, V. Raman, N. Ramirez, et al. 2009. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cells. Oncogene 28:2940-2947.
37. Ando, K., F. Takahashi, S. Motojima, K. Nakashima, N. Kaneko, K. Hoshi, et al. 2013. Possible role for tocilizumab, as anti-interleukin-6 receptor antibody, in treating cancer cachexia. J. Clin. Oncol. doi:10.1200/JCO.2012.44.2020.
38. Ohe, Y., E. R. Podack, K. J. Olsen, Y. Miyahara, K. Miura, H. Saito, et al. 1993. Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumour growth rate but cause weight loss and shortened survival in syngeneic mice. Br. J. Cancer 67:939-944.
39. Taylor, J. 2011. The obesity paradox. Eur. Heart J. 32:1575-1576.
40. Golledge, J., O. Cronin, V. Iyer, B. Bradshaw, J. V. Moxon, and M. A. Cunningham . 2013. Body mass index is inversely associated with mortality in patients with peripheral vascular disease. Atherosclerosis 229:549-555.
41. Hakimi, A. A., H. Furberg, E. C. Zabor, A. Jacobsen, N. Schultz, G. Ciriello, et al. 2013. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. J. Natl Cancer Inst. 105:1862-1870.
42. Murphy, R. A., M. S. Wilke, M. Perrine, M. Pawlowicz, M. Mourtzakis, J. R. Lieffers, et al. 2010. Loss of adipose tissue and plasma phospholipids: relationship to survival in advanced cancer patients. Clin. Nutr. 29:482-487.
43. Fouladiun, M., U. Körner, I. Bosaeus, P. Daneryd, A. Hyltander, and K. G. Lundholm . 2005. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care-correlations with food intake, metabolism, exercise capacity, and hormones. Cancer 103:2189-2198.
44. Kendler, D. L., J. L. Borges, R. A. Fielding, A. Itabashi, D. Krueger, K. Mulligan, et al. 2013. The Official Positions of the International Society for Clinical Densitometry: indications of Use and Reporting of DXA for Body Composition. J. Clin. Densitom. 16:496-507.